ADAG logo

ADAG Adagene Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.01
+0.19 (+10.44%)

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking a…

Market Cap: $75.67Mwww.adagene.com

Price

No data yet.

Social Signal Score

51
5d
60
1 mentions
—
30d
48
4 mentions
—
60d
48
5 mentions
—
90d
46
9 mentions
—
news: 9

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$8.25+310.4%
Low $7Median $8High $10
Current Consensus

Revenue

$1.62M
$0.00$2.93M$5.86M$8.79M
Mar 2019Jun 2026

Analyst Estimates

FY2025
$-0.50
$-0.58–$-0.42
2 analysts
FY2026
$-0.54
$-0.77–$-0.39
4 analysts
FY2027
$-0.76
$-0.81–$-0.71
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Peter Luo
Sector
Healthcare
Industry
Biotechnology
Employees
128
Beta
0.54
Country
CN
Piotroski score
4 / 9 (Middling)
Altman Z-score
-1.66
www.adagene.com